Medical
-
MannKind and Rose Pharma have announced a collaboration agreement that gives Rose a worldwide license for development of its ROSE-010 rapid-acting GLP-1 as an inhaled therapy for weight loss using MannKind’s Technosphere dry powder technology.… Read more . . .
-
AirNexis Therapeutics has announced that a Chinese Phase 2b study of AN01 (HSK39004) PDE3/4 inhibitor DPI in COPD patients that was conducted by Haisco Pharmaceutical met its primary endpoint. AirNexis launched in early 2026 with… Read more . . .
-
Chinese biotech Rezubio has announced the initiation of a Phase 1 PK/PD study of RZ-520, which Rezubio describes as “a novel inhaled therapeutic drug candidate for the treatment of chronic respiratory diseases.” According to Rezubio,… Read more . . .
-
According to Liquidia, the FDA has granted Fast Track designation to the company’s Yutrepia inhaled dry powder treprostinil for the treatment of Raynaud’s phenomenon associated with systemic sclerosis (SSc-RP.). Yutrepia is currently approved in the… Read more . . .
-
Milestone Pharmaceuticals has announced the initiation of the Phase 3 ReVeRA-301 study of etripamil nasal spray in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial is expected to enroll about 150 patients who… Read more . . .
-
NeOnc Technologies announced that the Phase 2a NEO100-01 study of NEO100 intranasal perillyl alcohol in patients with Grade 3 and Grade 4 IDH1-mutant gliomas met its primary endpoint, achieving a 48.9% 6-month progression-free survival rate.… Read more . . .
-
Zydus Lifesciences has announced the launch of its Revahale revefenacin inhalation solution in India. The company highlights that Revahale is the country’s first once-daily nubulized LAMA for the treatment of COPD, noting that the inhalation… Read more . . .
-
MannKind Corporation announced that the Phase 1b INFLO-1 safety and tolerability trial of its nintedanib dry powder inhaler met its primary endpoint, demonstrating safety and tolerability. The multiple ascending dose study enrolled 27 patients with… Read more . . .
-
US-based biopharm Revagenix announced that it has initiated a Phase 1 trial of Rev-56, which it describes as an “inhaled, anti-pseudomonal therapy for non-cystic fibrosis bronchiectasis (NCFB).” The first part of the study will evaluate… Read more . . .
-
Vistagen has announced that the Phase 3 PALISADE-4 public speaking challenge study of intranasal fasedienol (PH94B) for the treatment of social anxiety disorder failed to meet its primary endpoint. In December 2025, the company announced… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here


